FT576 in Subjects With Multiple Myeloma
Phase 1 Completed
31 enrolled
Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy
Phase 1 Completed
14 enrolled
Generic Plerixafor Efficacy of Autologous Hematopoietic Stem Cell Transplantation
Phase 1 Completed
6 enrolled
A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma
Phase 1 Completed
78 enrolled
Phase 1 Trial of CXD101 in Patients With Advanced Cancer
Phase 1 Completed
51 enrolled
Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma
Phase 1 Completed
26 enrolled
Safety Study of LBH589 When Given in Combination With Lenalidomide and Dexamethasone in Adult Patients With Multiple Myeloma.
Phase 1 Completed
46 enrolled
A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma
Phase 1 Completed
79 enrolled
Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma
Phase 1 Completed
11 enrolled
Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia
Phase 1 Completed
55 enrolled
A Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion With or Without Subcutaneous Recombinant Human Interleukin-2 (rhIL-2) Following Autologous Stem Cell Transplant for Multiple Myeloma (MM)
Phase 1 Completed
15 enrolled
Vaccination With PD-L1 Peptide Against Multiple Myeloma
Phase 1 Completed
10 enrolled
Vorinostat and Lenalidomide After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma
Phase 1 Completed
19 enrolled
PET Imaging of Cancer Patients Using [18F]-SKI-249380, a Radiolabeled Dasatinib-Derivative
Phase 1 Completed
11 enrolled
Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Phase 1 Completed
34 enrolled
Hydroxychloroquine and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Phase 1 Completed
25 enrolled
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
Phase 1 Completed
131 enrolled
Chemotherapy Plus Donor White Blood Cell Infusion in Treating Patients With Relapsed Hematologic Cancer Following Donor Peripheral Stem Cell Transplantation
Phase 1 Completed
Nelfinavir Mesylate and Bortezomib in Treating Patients With Relapsed or Progressive Advanced Hematologic Cancer
Phase 1 Completed
18 enrolled
Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) Patients
Phase 1 Completed
77 enrolled
Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
Phase 1 Completed
7 enrolled
Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia
Phase 1 Completed
70 enrolled
Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan, Melphalan, and Autologous Peripheral Stem Cell Transplant in Treating Patients With Previously Treated Multiple Myeloma
Phase 1 Completed
30 enrolled
T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer
Phase 1 Completed
41 enrolled
Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma
Phase 1 Completed
38 enrolled
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase 1 Completed
29 enrolled
Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer
Phase 1 Completed
29 enrolled
Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant
Phase 1 Completed
46 enrolled 11 charts
Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies
Phase 1 Completed
48 enrolled 26 charts
Study of Intravenously Administered SNS-032 in Patients With Advanced B-lymphoid Malignancies
Phase 1 Completed
21 enrolled
Bone Marrow Transplantation With Specially Treated Bone Marrow in Treating Patients With Hematologic Cancer That Have Not Responded to Previous Therapy
Phase 1 Completed
5 enrolled
Safety Study Looking at the Use of a Natural Killer Cell Line Against Hematological Malignancies
Phase 1 Completed
8 enrolled
Combination of Lenalidomide and Autologous Mature Dendritic Cells Pulsed With KRN7000 in Myeloma
Phase 1 Completed
6 enrolled
Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid Malignancies
Phase 1 Completed
145 enrolled
Safety and Dose Study of GRN163L Administered to Treat Patients With Refractory or Relapsed Multiple Myeloma
Phase 1 Completed
20 enrolled
Safety and Dose Study of GRN163L and Velcade to Treat Patients With Refractory or Relapsed Myeloma
Phase 1 Completed
40 enrolled
Phase I Study of OPB-51602 in Patients With Hematologic Malignancies
Phase 1 Completed
20 enrolled 6 charts
A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma
Phase 1 Completed
30 enrolled
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy
Phase 1 Completed
30 enrolled
Pharmacokinetic Study of Palifermin in Subjects Receiving Radiation Therapy and Chemotherapy Followed by Blood Stem Cell Support
Phase 1 Completed
25 enrolled
EMD 121974 in Treating Patients With Locally Advanced or Metastatic Cancer
Phase 1 Completed
40 enrolled
Interleukin-12 in Treating Patients With Hematologic Cancers or Solid Tumors
Phase 1 Completed
Interleukin-2 Following Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
Phase 1 Completed
P05538
Phase 1 Completed
41 enrolled
Bortezomib in Treating Patients With Multiple Myeloma Who Have Undergone an Autologous Peripheral Blood Stem Cell Transplant
Phase 1 Completed
15 enrolled
Treated T Cells Followed by a Stem Cell Transplant in Treating Patients With Multiple Myeloma
Phase 1 Completed
12 enrolled
Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Phase 1 Completed
36 enrolled
Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer
Phase 1 Completed
5 enrolled
Arsenic Trioxide in Treating Patients With Advanced Hematologic Cancer
Phase 1 Completed
Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy
Phase 1 Completed